ProQR Therapeutics NV PRQR.OQ PRQR.O is expected to show a fall in quarterly revenue when it reports results on March 10 (estimated) for the period ending December 31 2024
The Leiden Zuid-holland-based company is expected to report a 5.2% decrease in revenue to €5.894 million from €6.22 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for ProQR Therapeutics NV is for a loss of 9 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for ProQR Therapeutics NV is $10.00, above its last closing price of $1.94.
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.10 | -0.11 | -0.10 | Beat | 5.2 |
Jun. 30 2024 | -0.11 | -0.12 | -0.03 | Beat | 75.9 |
Mar. 31 2024 | -0.12 | -0.11 | -0.09 | Beat | 17.8 |
Dec. 31 2023 | -0.10 | 0.01 | -0.07 | Missed | -745.2 |
Sep. 30 2023 | -0.10 | -0.09 | -0.07 | Beat | 17.8 |
Jun. 30 2023 | -0.11 | -0.11 | -0.10 | Beat | 10 |
Mar. 31 2023 | -0.09 | -0.12 | -0.11 | Beat | 6.5 |
Dec. 31 2022 | -0.17 | -0.18 | -0.16 | Beat | 10.4 |
This summary was machine generated March 7 at 12:39 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。